ArticleFrontiers in pharmacology2026
Phillygenin suppresses hepatocellular carcinoma progression by modulating the TNF signaling pathway and TCA cycle metabolism.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phillygenin (PLE) is a bioactive constituent of Methods: The effect of PLE on HCCLM3 and Hep3B tumor cells was assessed using immunofluorescence (IF) staining, TUNEL assay, qRT-PCR, and Western blotting experimental methodology. RNA-sequencing (RNA-seq) was used to detect changes in gene expression and to explore the gene targets and related pathways. Liquid chromatography-mass spectrometry (LC-MS) was used to identify the effects of PLE on primary metabolite targets and metabolism-related pathways. Tumor xenograft models were used for Results: PLE inhibited HCC cell proliferation through the inhibition of cell cycle progression and induction of cell apoptosis Conclusion: PLE exerts antitumor effects in HCC through the coordinated regulation of tricarboxylic acid (TCA) cycle metabolism while simultaneously inhibiting the TNF signaling pathway, highlighting its potential as a candidate antitumor drug for the treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.